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demonstration that mutation of the glycine transporter can 
be associated with NKH in humans.
Introduction
Although glycine is the smallest amino acid, it is consid-
ered a conditionally essential amino acid, as de novo syn-
thesis may not be sufficient (Wang et al. 2013). It is essen-
tial for various processes in the body, including protein, 
glutathione, creatine, purine, heme, and serine synthesis 
(Dai et al. 2013; Hall 1998). It is also essential for bile acid 
conjugation (Hafkenscheid and Hectors 1975), as well as 
playing an important role in immune modulation through 
the glycine-gated chloride channels (Zhong et al. 2003). 
Moreover, glycine acts as an inhibitory neurotransmitter 
Abstract Glycine cleavage system (GCS) catalyzes the 
degradation of glycine and disruption of its components 
encoded by GLDC, AMT and GCSH are the only known 
causes of glycine encephalopathy, also known as non-
ketotic hyperglycinemia (NKH). In this report, we describe 
a consanguineous family with one child who presented 
with NKH, but harbored no pathogenic variants in any 
of the three genes linked to this condition. Whole-exome 
sequencing revealed a novel homozygous missense vari-
ant in exon 9 of SLC6A9 NM_201649.3: c.1219 A>G 
(p.Ser407Gly) that segregates with the disease within the 
family. This variant replaces the highly conserved S407 in 
the ion-binding site of this glycine transporter and is pre-
dicted to disrupt its function. In murine model, knockout 
of Slc6a9 is associated with equivalent phenotype of NKH, 
namely respiratory distress and hypotonia. This is the first 
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in central nervous system (CNS) by hyperpolarizing the 
post-synaptic glycinergic neurons (Legendre 2001). Gly-
cine levels are controlled by two main mechanisms; first, 
glycine degradation, mainly by the Glycine Cleavage Sys-
tem (GCS) and to a lesser extent formation of serine (Wang 
et al. 2013), and second, by glycine transport system which 
is mediated by two sodium-dependent carriers, mainly 
GLYT1 and GLYT2. Glycine Transporter 1 (GlyT1) bal-
ances the extracellular glycine concentration predomi-
nantly in CNS (Betz et al. 2006).
Disruption of the GCS leads to glycine encephalopathy 
or non-ketotic hyperglycinemia (NKH), where CSF-to-
plasma glycine ratio is elevated. In utero, fetal hiccups and 
myoclonus might be noticed, which may persist after deliv-
ery in addition to hypotonia and respiratory disturbances. 
Later, in life, patients develop seizures and intellectual dis-
ability (Dalla Bernardina et al. 1979). Nearly all cases of 
NKH have been found to harbor disease-causing autosomal 
recessive variants in the genes encoding the different com-
ponents of the GCS: glycine decarboxylase (GLDC), which 
encodes P protein, aminomethyltransferase gene (AMT), 
which encodes T protein; and glycine cleavage system H 
gene (GCSH), which encodes H protein (Applegarth and 
Toone 2006).
Glycine encephalopathy caused by glycine transporter 
system was proposed as a distinct entity only once in an 
atypical NKH case. Mayor et al. (1984) described a patient 
who presented with classic symptoms of NKH; however, 
no confirmatory mutation analysis was conducted (Mayor 
et al. 1984). In this study, we suggest that NKH can, 
indeed, be caused by mutation of the glycine transporter, 




The index case underwent full clinical evaluation by a 
clinical geneticist for her multisystem disorder (see below). 
Standard clinical-exome consent was obtained from the 
proband’s parents. Blood samples were collected from 
index case and parents in EDTA tubes for DNA extraction, 
and trio whole-exome sequencing analysis (proband and 
both parents) was performed at a CLIA-certified clinical 
diagnostic laboratory.
Exome analysis
Genomic DNA was extracted from whole blood for the 
affected proband and family members (both unaffected par-
ents and unaffected sister). Exome sequencing at GeneDx 
was performed on exon targets isolated by capture using 
the Agilent Clinical Research Exome kit (Agilent Tech-
nologies, Santa Clara, CA). The sequencing methodology 
and variant interpretation protocol have been previously 
described (Tanaka et al. 2015). The general assertion cri-
teria for variant classification are publicly available on the 
GeneDx ClinVar submission page (http://www.ncbi.nlm.
nih.gov/clinvar/submitters/26957/).
Percent covered at 10× for the proband was 96.37, 
while that for mother and father was 96.22 and 96.42, 
respectively. Mean coverage for the proband was 132.67, 
while that for mother and father was 116.72 and 130.07, 
respectively. Sanger sequencing of AMT, GLDC, and 
GCSH, which are mutated in NKH, was performed to fur-
ther rule out mutation of any of these genes as the cause of 
the patient’s phenotype.
Computational structural analysis of mutants
Sequences were retrieved from the Uniprot database. 
BLAST and SwissModel (Arnold et al. 2006) were used to 
search for suitable structural templates in the Protein Data 
Bank (PDB). SwissModel was used to produce homology 
models. Models were manually inspected and evaluated 
using the Pymol program (pymol.org).
Results
Clinical report
The index case is a 15-month-old girl product of full-term 
pregnancy via normal spontaneous vaginal delivery, born 
to first cousin Saudi parents (Fig. 1). Pregnancy was com-
plicated by polyhydramnios, and there was no history of 
abnormal fetal movements. Maternal obstetric history 
was significant for two first trimester miscarriages and a 
healthy older daughter (G4P2 + 2) with the same part-
ner. Birth growth parameters include weight 2900 g (−0.8 
SD), length 50 cm (0.45 SD), and OFC 34.5 cm (0.52 SD). 
Shortly, after birth, she developed shallow breathing and 
acute respiratory distress that required intubation and ven-
tilatory support for 1 month prior to successful extubation 
in the NICU. Neonatal course, starting at age of 3 days, 
was further complicated by seizure-like episodes, which 
were medically controlled with phenobarbital and pheny-
toin. Subsequently, it was noted that these symptoms were 
likely exaggerated startle reflexes provoked by sudden 
loud sounds and tactile stimulation, i.e., hyperekplexia. 
All antiepileptic medications were gradually tapered, as 
such seizure-like episodes and startle reflexes improved 
over time and completely subsided by age 6 months. In 
addition, the patient had hypotonia, weak cry, difficulty 
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swallowing which lead to aspiration, multiple hospi-
talizations, and eventually insertion of gastrostomy tube. 
Clinical follow-up at 15 months of age showed failure to 
thrive and microcephaly: weight was 6.8 kg (−2.8 SD), 
length 73 cm (−1.6 SD), and head circumference 40.5 cm 
(−3.7 SD). Subtle facial dysmorphic features were noted: 
microcephaly, broad forehead, esotropia, low set ears, 
retrognathia, deep prominent philtrum, and sparse eye-
brows (Fig. 1). Developmentally, she had global delay, 
including motor and speech. Neurological examination 
showed central hypotonia with brisk deep tendon reflexes 
peripherally; musculoskeletal examination showed bilat-
eral joint laxity around the elbows with bilateral club feet. 
Rest of clinical exam was unremarkable. The following 
Fig. 1  a Family pedigree, b esotropia and microcephaly, broad fore-
head, esotropia, low set ears, retrognathia, deep prominent philtrum 
and sparse eyebrows, c selected MR image of the brain at the level of 
basal ganglia, coronal T2-WI shows bilateral subinsular white matter 
hyper intensity (arrows) and right head of caudate atrophy with a tiny 
cyst (star), d axial T2-WI shows bilateral scattered subcortical and 
periventricular white matter hyperintensities (arrows)
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laboratory investigations were unremarkable: newborn 
screening, CBC, renal function, liver function, ammonia, 
serum lactic acid, urine organic acids, chromosomal anal-
ysis, CGH microarray, and clinical sequencing of AMT, 
GLDC, and GCSH genes.
Plasma amino acids showed mild elevation of gly-
cine at 288 µmol/L (normal: 73–241). Urine amino acids 
also showed mild elevation of glycine at 393 µM/mM Cr 
(normal: 110–356), methionine at 66 µM/mM Cr (nor-
mal: 7–29), ethanolamine at 98 µM/mM Cr (normal: not 
detected), and ornithine at 14 µM/mM Cr (normal: <8). 
This prompted CSF amino acid analysis, which revealed 
elevated glycine at 21 µmol/L (normal: 2.2–14.2) and CSF/
plasma glycine ratio, was elevated at 0.07(normal: <0.02). 
Electroencephalogram (EEG) and echocardiogram were 
both normal. Skeletal survey showed right developmen-
tal dysplasia of the hip (DDH), superior dislocation of the 
right proximal femur, and bilateral club feet. Magnetic res-
onance imaging (MRI) of the brain showed bilateral subin-
sular white matter T2 hyperintensity, right head of caudate 
atrophy with tiny cyst, and bilateral scattered subcortical 
and periventricular white matter changes (Fig. 1).
Whole-exome sequencing showed a novel homozy-
gous missense variant in exon 9 of the SLC6A9 gene: 
NM_201649.3: c.1219 A>G (p.Ser407Gly), as both parents 
and the older sister were heterozygous for this variant. This 
missense variant has not previously been reported in any of 
the publicly available population catalogs (1000 Genomes, 
NHLBI ESP/EVS, ExAC), >1400 individuals of Arabic 
background in GeneDx internal exome database, or 2000 
ethnically matched (Saudi) exomes from the Saudi Human 
Genome Program database. Moreover, the discovered vari-
ant resides within the autozygome. This missense change 
is predicted to be pathogenic by various in silico models: 
SIFT (0.003), PolyPhen (1) and CADD (26.9).
The SLC6A9 protein can be modelled based on the crys-
tal structure of the 46 % identical dopamine transporter 
(PDB accession 4xpa and related entries) from Drosophila, 
or the 43 % identical human sodium-dependent serotonin 
transporter (PDB 5i6z). In both these template sequences 
and structures, the serine at position 407 is conserved. 
Ser407 is located in the middle of transmembrane helix 7. 
Although it is not in direct contact with the ligand chan-
nel, and positioned in a distance of about 7–10 Å to the 
ligand, Ser407 contributes to a cavity that binds a chloride 
and sodium ion in the highly similar dopamine transporter 
(Wang et al. 2015) (Fig. 2). This ion-binding site allows 
the receptor to correlate substrate transport with pre-exist-
ing chloride and sodium gradients. The ion-binding site 
is strictly conserved between the Drosophila dopamine 
receptor and human SLC6A9. S407G is a non-conserv-
ative replacement, where the small and hydrophilic Ser 
is replaced by a more flexible more hydrophobic glycine 
without any side chain. This replacement changes the shape 
and chemical properties of the ion-binding site and, hence, 
disrupts normal functioning of the transporter.
Fig. 2  3D homology model of human SLC6A9, based on the dopa-
mine transporter (PDB 4xpa). The dopamine analogue 3,4-dichlo-
rophenethylamine (yellow), sodium (magenta), and chloride (cyan) 
ions have been taken over from the dopamine receptor structure 
that served as template. The bound ions are expected to be located 
in the wild-type (but not the S406 mutant) SLC6A9, as they are in 
the dopamine transporter, because of strict conservation of the ion-
binding site. However, the dopamine analogue is of course replaced 
by glycine in SLC6A9, and the dopamine analogue is only displayed 
to illustrate the location of S406 with respect to the ligand molecule
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Discussion
In this report, we present the first case in the literature of 
presumptive glycine transporter defect in association with a 
novel variant in SLC6A9. Solute Carrier Family 6 (SLC6), 
also known as neurotransmitters transporters or Na+/Cl− 
dependent transporter family, is a group of transporters 
for neurotransmitters, proteinogenic amino acids, betaine, 
taurine, and creatine. SLC6 is further subdivided into four 
subfamilies; monoamine transporters (SLC6A2, SLC6A3, 
and SLC6A4), GABA transporters (SLC6A1, SLC6A13, 
and SLC6A11), glycine transporters (SLC6A9, SLC6A5, 
SLC6A14, and SLC6A7), and neutral amino acid trans-
porter (SLC6A19, SLC6A15, and SLC6A18) (Alexander 
et al. 2015).
SLC6A9 encodes GlyT1, which is located in the plasma 
membrane, predominantly in glial cells and neurons. Its 
main function is to modulate glycine level in the synapse by 
transporting glycine from the synaptic cleft into cells. Vari-
ous experiments showed evidence of crucial role of GlyT1 
in the development of basic respiratory pattern and tone as 
GlyT1 deficiency (Slc6a9 knockout) in mice causes severe 
respiratory distress and death shortly after birth (Chalphin 
and Saha 2010; Gomeza et al. 2003), which faithfully reca-
pitulates our patient’s acute respiratory distress postnatally.
Mayor et al. (1984) case presented with typical NKH 
symptoms, however, GCS functional study was normal. 
Furthermore, the glycine transport system was absent in 
brain autopsy, but no confirmatory mutation analysis was 
conducted (Mayor et al. 1984).
The presented patient shared similarities with other 
NKH patients, regarding the age of onset and various clini-
cal features, such as hypotonia, early respiratory distress, 
myoclonic jerks, and seizures (Table 1), although she also 
exhibited subtle facial dysmorphic features that have not 
been described in patients with NKH. More importantly, 
burst suppression pattern on EEG, which is commonly 
observed in classical NKH, was not observed in this patient 
as EEG was reportedly normal. In addition, biochemi-
cal profile showed elevation of CSF/plasma glycine ratio 
(0.07), in contrast to classic NKH patients, where CSF/
plasma glycine ratio is usually greater than 0.08. We also 
note that the proband’s exaggerated startle reflex during the 
first 6 months of age (hyperekplexia), has previously been 
reported as a feature in association with SLC6A5-related 
disorders (Arribas-Gonzalez et al. 2015; Dreissen and Tijs-
sen 2012; Michael Davis et al. 1993; Supplisson and Roux 
2002), but not in association with NKH, suggesting this 
feature might be a common finding between GlyT1 and 
GlyT2 systems. Another possible explanation for the star-
tle reflex could be due to the excitatory effect of glycine 
on the glutamatergic neurons through N-methyl-d-aspartic 
acid (NMDA) receptors, leading to depolarization of the 
post-synaptic neurons (Betz et al. 2006), even though such 
symptoms subsided after 6 months of age.
Long-term outcome for mice carrying heterozygous var-
iants in GlyT1 has previously been documented (Gomeza 
et al. 2003); however, mice carrying homozygous variants 
expired soon postnatally, rendering it very difficult to pre-
dict natural history from structural, developmental, and 
behavioral aspects. Hypomorphic mutants will potentially 
clarify the full phenotypic consequences of GlyT1 defi-
ciency in mouse to model what we observed in our human 
patient and we hope the reported variant can aid in the 
design of an appropriate knock-in strategy.
In summary, we report the first living human case car-
rying a homozygous missense variant in SLC6A9 and the 
associated phenotype includes: global developmental 
delay, hypotonia, subtle dysmorphic features, joint lax-
ity, and clubfeet; high plasma and CSF glycine levels with 
elevated CSF-to-plasma glycine ratio; and brain white mat-
ter changes. However, we acknowledge that the disease 
Table 1  Comparison between NKH and glycine transporter 1 defect
Feature NKH GlyT1 variant
Age of onset Neonatal or infantile Neonatal
Major clinical 
features
Respiratory distress requiring mechanical ventila-
tion, seizure, hypotonia, microcephaly, spastic 
quadriplegia, global developmental delay
Respiratory distress requiring mechanical ventilation, microcephaly 
hypotonia, joint laxity, exaggerated startle response, developmental 
dysplasia of the hip, global developmental delay
Facial dysmorphic 
features
None Broad forehead, esotropia, low set ears, retrognathia, deep prominent 




High CSF, plasma, and urine glycine High CSF, plasma, and urine glycine
MRI Delayed myelination, absent corpus callosum, brain 
atrophy, and dilatation of the ventricles. White 
matter changes
Atrophy in the caudate nucleus, white matter changes. Normal myeli-
nation.
EEG Burst suppression pattern Normal
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link we propose in this study is based on a single patient. 
Further research and additional reports of SLC6A9 variants 
are needed to elucidate the full SLC6A9-related phenotype 
and genotype spectrum in humans. In addition, as further 
delineation of various gene-related phenotypes and identi-
fication of more novel genes continue, future reanalysis of 
whole-exome sequencing data could help clarify if reported 
dysmorphic features are possibly associated with yet-to-be 
fully described genes.
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